ERBB2 and cancer: ERBB2 amplification was often mutually exclusive with canonical oncogenic alterations in GC (83.3%; 5/6) and CRC (60%; 3/5) cancer patients, reinforcing its likely importance in these cancer types (Figure 5, Supplementary Table 2).